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nﬂ  ammatory bowel disease (IBD) is 
mainly seen in developed, urbanized 
countries, and its incidence 
increased steeply at the beginning of 
the 20th century, concurrently with 
improved hygiene. Similar trends 
have been observed for allergic and 
autoimmune disorders, suggesting 
that a reduction in microbial burden 
contributes to disease pathogenesis. 
Apart from environmental factors 
playing a strong role, genetic factors are 
also involved in IBD, so it is regarded as 
a complex disorder. 
IBD can be classiﬁ  ed as Crohn 
disease (CD) or ulcerative colitis (UC). 
Although these two forms of IBD 
share similar clinical and pathological 
features, the disease is heterogeneous, 
with marked differences in clinical 
presentation, underlying genetic 
factors, and response to treatment. 
The differentiation between CD and 
UC has been debated for a long time. 
Elucidation of the underlying disease 
pathway(s) may help to resolve this 
debate and also provide important 
leads for novel therapeutic targets. 
Recent genetic studies have been fairly 
successful in identifying disease genes 
for CD, in particular, pointing toward 
an impaired integrity of the epithelial 
barrier (reviewed in [1]). However, 
a broad view of the underlying 
pathogenic mechanism in IBD is 
expected to come from complementary 
approaches, including gene expression 
proﬁ  ling using microarray studies.
Molecular Proﬁ  ling to Identify 
the Molecular Mechanisms 
Underlying IBD
In a study published in PLoS 
Medicine, Schreiber and coworkers 
have used a comprehensive gene 
expression approach to ﬁ  nd new 
genes and pathways relevant to the 
pathophysiology of IBD [2]. They took 
a close look at the genes differentially 
expressed in mucosal biopsies taken 
from the sigmoidal colons of ten 
individuals with UC, ten individuals 
with CD, and 11 control individuals 
(Figure 1). The genes were studied by 
hybridizing RNA from these biopsies to 
membranes spotted with some 23,000 
unique transcripts from the human 
genome. One of the strengths of this 
study is the access to tissue involved 
in the disease process, although the 
biopsies represent a mixed population 
of cells. 
The authors initially examined 
active disease tissues (i.e., from 
untreated patients), which comes 
with the risk of mainly seeing the 
consequence of the disease rather 
than the cause. Their experimental 
design is extremely robust for 
obtaining small but signiﬁ  cant 
differences in gene expression: 
ten measurements per gene were 
made for each sample, as the genes 
were spotted in duplicate and the 
experiments were repeated ﬁ  ve times. 
The authors were able to identify 
genes with at least a 1.2-fold change 
between groups, differences much 
smaller than commonly reported 
for these types of studies. Hence, 
the number of genes differentially 
expressed was rather large: 378 genes 
unique to CD, 150 genes unique 
to UC, and 122 genes differentially 
expressed in both groups, compared 
to normal control tissue. Although 
both UC and CD share a general 
inﬂ  ammation proﬁ  le, these results 
strengthen earlier suggestions that 
CD and UC are, at the molecular 
level, two related yet different forms 
of chronic intestinal inﬂ  ammation. 
Follow-up studies indicated that most 
of these differentially expressed genes 
may not be IBD-speciﬁ  c, but rather a 
consequence of colon inﬂ  ammation.
Three other microarray studies on 
IBD have been published, but there is 
little overlap between the individual 
genes identiﬁ  ed [3–5]. Although 
the experimental designs of these 
four studies differ signiﬁ  cantly, it is 
interesting that the studies all point to 
the involvement of similar biological 
processes: immune-related processes, 
oncogenesis/cell proliferation/growth, 
and structure/permeability-related 
processes.
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Figure 1. Colonoscopy Images
Above are colonoscopy images from a 
healthy control patient with a noninﬂ  amed 
colon (left) and from patients with highly 
inﬂ  amed CD (middle) and UC (right). Below 
are resulting heat maps of differentially 
expressed genes identiﬁ  ed for control 
patients versus CD patients (left ) and 
control patients versus UC patients (right). 
(Image: Costello et al. [2]) PLoS Medicine  |  www.plosmedicine.org 0720
What Can Be Learned from 
These Studies?
Gene-expression proﬁ  ling studies 
appear to hold much promise. In 
cancer studies, this promise has 
been met with the identiﬁ  cation of 
many proﬁ  les that can be used to 
classify different tumor stages or to 
predict response to therapy. The 
gene-expression changes in tumor 
tissues are, in general, much more 
pronounced than those seen in 
other diseased tissues. A number of 
potentially interesting, new leads for 
therapeutic targets or disease diagnosis 
have come from Costello et al.’s study. 
Upregulation of cancer-related genes, 
such as TFF1 and the gene that encodes 
the Wnt signaling molecule CSNK1D, 
is very speciﬁ  c to the UC proﬁ  le, and 
may point toward these genes playing a 
role in the increased risk of malignant 
transformation for patients with a 
long history of UC. Uthoff et al. also 
suggested a potential role for the Wnt 
signaling pathway in UC carcinogenesis 
in an earlier but much smaller study 
[6], but this needs to be further 
investigated. It is encouraging to learn 
that many of the genes now being 
identiﬁ  ed conﬁ  rm the ideas on disease 
pathogenesis that have developed 
recently as a result of genetic studies, 
namely, that there is impaired integrity 
of the epithelial barrier. Hence, 
Costello et al.’s study may further 
our understanding of the underlying 
disease mechanism.
Another interesting avenue for gene 
expression data is its use in selecting 
novel disease gene candidates. Costello 
et al. have identiﬁ  ed 59 differentially 
expressed genes that map to IBD 
linkage regions. Genetic variants 
contributing to a complex disease like 
IBD are expected to be regulatory 
variants resulting in differential gene 
expression, rather than structural 
variants (amino acid substitutions). 
Although the majority of these 59 
genes are more the consequence of 
the disease than the cause, current 
technology and recent accessibility to 
large numbers of single nucleotide 
polymorphisms make it feasible to test 
them for genetic association.
Looking Toward the Future
As gene expression studies mainly 
generate hypotheses, they provide 
a basis for further detailed gene 
function studies. However, the majority 
of genes included in these types of 
studies have an unknown function 
or a limited functional annotation 
at best, making it difﬁ  cult to identify 
functional relationships between 
genes. This situation is expected to 
change with the ongoing large-scale 
functional genomics studies now 
being conducted. Nevertheless, genes 
with an unknown function can still be 
excellent candidate genes for testing by 
genetic association. Since expression 
studies mainly highlight the perturbed 
pathways involved, and genetic studies 
point to critical players in disease 
pathways, it is obvious that much can 
be gained from integrating the two. 
As Schreiber’s research group was 
instrumental in identifying DLG5 as 
one of the IBD genes, this group is in 
an excellent position to perform both 
types of studies [7]. 
A future application might be to use 
disease-speciﬁ  c signatures as predictive 
diagnostic tools for distinguishing 
CD from UC. Since mucosal biopsies 
are invasive and burdensome for the 
patients, it would be interesting to 
determine whether similar patterns of 
expression can also be obtained from 
peripheral blood.  
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